NYSEAMERICAN:AST - Asterias Biotherapeutics Stock Price, Price Target & More

$1.30 -0.05 (-3.70 %)
(As of 04/22/2018 06:19 AM ET)
Previous Close$1.30
Today's Range$1.30 - $1.35
52-Week Range$1.25 - $4.30
Volume138,682 shs
Average Volume225,346 shs
Market Capitalization$102.89 million
P/E RatioN/A
Dividend YieldN/A
Beta1.02

About Asterias Biotherapeutics (NYSEAMERICAN:AST)

Asterias Biotherapeutics logoAsterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.

Receive AST News and Ratings via Email

Sign-up to receive the latest news and ratings for AST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:AST
CUSIPN/A
Phone+1-510-4563805

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-403.38%
Return on Equity-79.80%
Return on Assets-59.45%

Miscellaneous

EmployeesN/A
Outstanding Shares54,200,000

How to Become a New Pot Stock Millionaire

Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions

What is Asterias Biotherapeutics' stock symbol?

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics (NYSEAMERICAN:AST) issued its earnings results on Thursday, March, 15th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.03. The biotechnology company had revenue of $0.03 million for the quarter, compared to analysts' expectations of $1.08 million. Asterias Biotherapeutics had a negative return on equity of 79.80% and a negative net margin of 403.38%. View Asterias Biotherapeutics' Earnings History.

When is Asterias Biotherapeutics' next earnings date?

Asterias Biotherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Asterias Biotherapeutics.

What price target have analysts set for AST?

2 analysts have issued 12 month price targets for Asterias Biotherapeutics' stock. Their forecasts range from $6.00 to $11.00. On average, they anticipate Asterias Biotherapeutics' stock price to reach $8.50 in the next year. View Analyst Ratings for Asterias Biotherapeutics.

Are investors shorting Asterias Biotherapeutics?

Asterias Biotherapeutics saw a decrease in short interest in March. As of March 29th, there was short interest totalling 3,593,338 shares, a decrease of 1.9% from the March 15th total of 3,661,754 shares. Based on an average daily trading volume, of 317,536 shares, the days-to-cover ratio is currently 11.3 days. Currently, 11.4% of the shares of the stock are sold short.

Who are some of Asterias Biotherapeutics' key competitors?

Who are Asterias Biotherapeutics' key executives?

Asterias Biotherapeutics' management team includes the folowing people:
  • Dr. Katharine E. Spink, Consultant (Age 44)
  • Dr. Jane S. Lebkowski Ph.D., Scientific Advisor (Age 62)
  • Mr. Stephen L. Cartt, Advisor & Director (Age 55)
  • Mr. Michael H. Mulroy, Chief Exec. Officer, Pres & Director (Age 52)
  • Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 42)

Has Asterias Biotherapeutics been receiving favorable news coverage?

News coverage about AST stock has been trending positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Asterias Biotherapeutics earned a news impact score of 0.44 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 45.71 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Asterias Biotherapeutics?

Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Asterias Biotherapeutics' stock price today?

One share of AST stock can currently be purchased for approximately $1.30.

How big of a company is Asterias Biotherapeutics?

Asterias Biotherapeutics has a market capitalization of $102.89 million.

How can I contact Asterias Biotherapeutics?

Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.


MarketBeat Community Rating for Asterias Biotherapeutics (AST)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  97
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe AST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Asterias Biotherapeutics (NYSEAMERICAN:AST) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Asterias Biotherapeutics in the last 12 months. Their average twelve-month price target is $8.50, suggesting that the stock has a possible upside of 553.85%. The high price target for AST is $11.00 and the low price target for AST is $6.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.50$9.6667$11.00$11.3333
Price Target Upside: 553.85% upside395.73% upside340.00% upside228.50% upside

Asterias Biotherapeutics (NYSEAMERICAN:AST) Consensus Price Target History

Price Target History for Asterias Biotherapeutics (NYSEAMERICAN:AST)

Asterias Biotherapeutics (NYSEAMERICAN:AST) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
3/27/2018B. RileySet Price TargetBuy$6.00View Rating Details
3/16/2018HC WainwrightSet Price TargetBuy$11.00View Rating Details
4/4/2017LaidlawInitiated CoverageBuy -> Buy$12.00View Rating Details
3/7/2017FBR & CoBoost Price TargetOutperform$6.00 -> $10.00View Rating Details
5/23/2016Chardan CapitalInitiated CoverageBuy$5.50View Rating Details
5/17/2016Rodman & RenshawReiterated RatingBuy$10.00View Rating Details
(Data available from 4/22/2016 forward)

Earnings

Asterias Biotherapeutics (NYSEAMERICAN:AST) Earnings History and Estimates Chart

Earnings by Quarter for Asterias Biotherapeutics (NYSEAMERICAN:AST)

Asterias Biotherapeutics (NYSEAMERICAN:AST) Earnings Estimates

2018 EPS Consensus Estimate: ($0.44)
2019 EPS Consensus Estimate: ($0.49)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.13)($0.13)($0.13)
Q2 20181($0.12)($0.12)($0.12)
Q3 20181($0.10)($0.10)($0.10)
Q4 20181($0.09)($0.09)($0.09)
Q1 20191($0.10)($0.10)($0.10)
Q2 20191($0.11)($0.11)($0.11)
Q3 20191($0.13)($0.13)($0.13)
Q4 20191($0.15)($0.15)($0.15)

Asterias Biotherapeutics (NYSEAMERICAN AST) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018($0.11)N/AView Earnings Details
3/15/2018Q4 2017($0.15)($0.12)$1.08 million$0.03 millionViewN/AView Earnings Details
11/14/2017Q3 2017($0.15)($0.15)$1.43 million$1.69 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.18)($0.18)$1.25 million$0.32 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.18)($0.17)$1.63 million$2.01 millionViewN/AView Earnings Details
3/28/2017Q4($0.17)($0.18)$2.81 million$1.75 millionViewN/AView Earnings Details
11/14/2016Q316($0.17)($0.24)$1.50 million$2.10 millionViewN/AView Earnings Details
8/15/2016Q216($0.19)($0.12)$1.14 million$1.53 millionViewListenView Earnings Details
5/16/2016Q116($0.14)($0.27)$1.60 millionViewListenView Earnings Details
3/29/2016Q415($0.13)($0.13)$1.07 million$0.61 millionViewListenView Earnings Details
11/9/2015Q315($0.11)($0.06)$1.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.11)($0.10)$0.10 million$0.77 millionViewListenView Earnings Details
5/7/2015($0.13)($0.14)$0.10 million$0.78 millionViewN/AView Earnings Details
3/10/2015($0.13)($0.11)$1.07 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.05)$0.09 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.09)$0.02 millionViewN/AView Earnings Details
5/12/2014Q1 2014($0.07)$0.06 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Asterias Biotherapeutics (NYSEAMERICAN:AST) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Asterias Biotherapeutics (NYSEAMERICAN AST) Insider Trading and Institutional Ownership History

Insider Trading History for Asterias Biotherapeutics (NYSEAMERICAN:AST)
Institutional Ownership by Quarter for Asterias Biotherapeutics (NYSEAMERICAN:AST)

Asterias Biotherapeutics (NYSEAMERICAN AST) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/26/2018Michael H MulroyInsiderBuy2,839$1.76$4,996.64View SEC Filing  
2/26/2018Michael H MulroyInsiderBuy2,255$2.22$5,006.10View SEC Filing  
1/25/2018Michael H MulroyInsiderBuy2,134$2.34$4,993.56View SEC Filing  
12/26/2017Michael H MulroyInsiderBuy2,247$2.22$4,988.34View SEC Filing  
11/27/2017Michael H MulroyInsiderBuy2,076$2.41$5,003.16View SEC Filing  
10/25/2017Michael H MulroyInsiderBuy1,939$2.55$4,944.45View SEC Filing  
9/25/2017Michael H. MulroyInsiderBuy1,537$3.25$4,995.25View SEC Filing  
1/9/2017Edward WirthInsiderSell3,415$4.60$15,709.003,415View SEC Filing  
1/9/2017Katharine E SpinkCOOSell4,781$4.60$21,992.604,781View SEC Filing  
10/6/2016Edward WirthInsiderSell3,415$4.12$14,069.80View SEC Filing  
10/6/2016Katharine E. SpinkCOOSell4,781$4.11$19,649.91View SEC Filing  
9/9/2016Edward WirthInsiderSell14,760$3.52$51,955.20View SEC Filing  
9/9/2016Katharine E. SpinkCOOSell19,336$3.52$68,062.72View SEC Filing  
6/30/2016Stephen Lahue CarttCEOBuy10,000$2.40$24,000.00260,000View SEC Filing  
6/29/2016Richard T LebuhnDirectorBuy5,000$2.38$11,900.0025,000View SEC Filing  
6/10/2016Stephen Lahue CarttCEOBuy50,000$2.93$146,500.00250,000View SEC Filing  
6/9/2016Alfred D KingsleyDirectorBuy4,000$2.93$11,720.009,000View SEC Filing  
5/13/2016Natale S RicciardiDirectorBuy14,706$3.39$49,853.3419,706View SEC Filing  
9/16/2015Cary PinkowskiDirectorSell409,000$0.0150$6,135.00
9/15/2015Edward WirthinsiderSell2,880$6.00$17,280.00View SEC Filing  
9/15/2015Katharine E. SpinkCOOSell3,760$6.00$22,560.00View SEC Filing  
9/14/2015Cary PinkowskiDirectorSell394,000$0.0150$5,910.00
6/25/2015Andrew ArnoDirectorBuy5,000$4.32$21,600.00View SEC Filing  
2/9/2015Pedro LichtingerCEOBuy128,205$3.90$499,999.50View SEC Filing  
10/1/2014Scarsdale Equities LlcMajor ShareholderBuy60,000$5.93$355,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Asterias Biotherapeutics (NYSEAMERICAN AST) News Headlines

Source:
DateHeadline
Asterias Biotherapeutics (AST) Raised to "Hold" at ValuEngineAsterias Biotherapeutics (AST) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - April 20 at 1:54 PM
Asterias Biotherapeutics (AST) PT Set at $12.00 by HC WainwrightAsterias Biotherapeutics (AST) PT Set at $12.00 by HC Wainwright
www.americanbankingnews.com - April 19 at 12:16 PM
Asterias Biotherapeutic: Spinal Injury Stem Cell Therapy PlayAsterias Biotherapeutic: Spinal Injury Stem Cell Therapy Play
seekingalpha.com - April 18 at 10:40 AM
Short Interest in Asterias Biotherapeutics (AST) Declines By 1.9%Short Interest in Asterias Biotherapeutics (AST) Declines By 1.9%
www.americanbankingnews.com - April 11 at 2:27 AM
Asterias Biotherapeutics (AST) Given a $12.00 Price Target at HC WainwrightAsterias Biotherapeutics (AST) Given a $12.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 10 at 11:38 PM
Asterias Biotherapeutics (AST) Given a $12.00 Price Target by HC Wainwright AnalystsAsterias Biotherapeutics (AST) Given a $12.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 10 at 9:45 AM
ValuEngine Upgrades Asterias Biotherapeutics (AST) to HoldValuEngine Upgrades Asterias Biotherapeutics (AST) to Hold
www.americanbankingnews.com - April 9 at 7:30 PM
HC Wainwright Reaffirms "Buy" Rating for Asterias Biotherapeutics (AST)HC Wainwright Reaffirms "Buy" Rating for Asterias Biotherapeutics (AST)
www.americanbankingnews.com - April 8 at 2:04 PM
Q1 2018 EPS Estimates for Asterias Biotherapeutics Inc Lifted by Analyst (AST)Q1 2018 EPS Estimates for Asterias Biotherapeutics Inc Lifted by Analyst (AST)
www.americanbankingnews.com - March 30 at 6:50 AM
Equities Analysts Offer Predictions for Asterias Biotherapeutics Incs Q1 2019 Earnings (AST)Equities Analysts Offer Predictions for Asterias Biotherapeutics Inc's Q1 2019 Earnings (AST)
www.americanbankingnews.com - March 29 at 8:28 AM
B. Riley Analysts Give Asterias Biotherapeutics (AST) a $6.00 Price TargetB. Riley Analysts Give Asterias Biotherapeutics (AST) a $6.00 Price Target
www.americanbankingnews.com - March 27 at 10:27 AM
Asterias Biotherapeutics Inc (AST) Sees Large Growth in Short InterestAsterias Biotherapeutics Inc (AST) Sees Large Growth in Short Interest
www.americanbankingnews.com - March 26 at 6:54 PM
Asterias Biotherapeutics (AST) PT Set at $6.00 by B. RileyAsterias Biotherapeutics (AST) PT Set at $6.00 by B. Riley
www.americanbankingnews.com - March 24 at 2:45 PM
Asterias Biotherapeutics (AST) Lowered to "Sell" at Zacks Investment ResearchAsterias Biotherapeutics (AST) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 20 at 5:56 PM
Asterias Biotherapeutics (AST) Given a $11.00 Price Target by HC Wainwright AnalystsAsterias Biotherapeutics (AST) Given a $11.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 16 at 7:47 PM
Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Developments - GlobeNewswire (press release)Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Developments - GlobeNewswire (press release)
globenewswire.com - March 16 at 3:37 PM
Asterias Biotherapeutics (AST) CEO Mike Mulroy on Q4 2017 Results - Earnings Call TranscriptAsterias Biotherapeutics' (AST) CEO Mike Mulroy on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 16 at 10:59 AM
Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent DevelopmentsAsterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Developments
finance.yahoo.com - March 16 at 10:59 AM
Asterias Biotherapeutics Inc Class A to Host Earnings CallAsterias Biotherapeutics Inc Class A to Host Earnings Call
finance.yahoo.com - March 15 at 3:37 PM
Is Astarta Holding NV.’s (WSE:AST) Balance Sheet A Threat To Its Future?Is Astarta Holding NV.’s (WSE:AST) Balance Sheet A Threat To Its Future?
finance.yahoo.com - March 13 at 9:42 AM
Asterias Biotherapeutics (AST) Set to Announce Quarterly Earnings on ThursdayAsterias Biotherapeutics (AST) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 10 at 8:04 PM
Asterias Biotherapeutics Inc (AST) Short Interest UpdateAsterias Biotherapeutics Inc (AST) Short Interest Update
www.americanbankingnews.com - March 9 at 6:22 PM
Asterias Biotherapeutics to Report Fourth Quarter and Full Year ... - GlobeNewswire (press release)Asterias Biotherapeutics to Report Fourth Quarter and Full Year ... - GlobeNewswire (press release)
globenewswire.com - March 9 at 3:42 PM
Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2017 Results on March 15, 2018Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2017 Results on March 15, 2018
finance.yahoo.com - March 9 at 10:19 AM
Asterias Biotherapeutics (AST) Reports Update on AST-OPC1 ... - StreetInsider.comAsterias Biotherapeutics (AST) Reports Update on AST-OPC1 ... - StreetInsider.com
www.streetinsider.com - March 1 at 3:33 PM
 Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
finance.yahoo.com - March 1 at 10:34 AM
Asterias Biotherapeutics Inc (AST) Sees Significant Growth in Short InterestAsterias Biotherapeutics Inc (AST) Sees Significant Growth in Short Interest
www.americanbankingnews.com - February 27 at 5:58 PM
B. Riley Weighs in on Asterias Biotherapeutics Incs FY2017 Earnings (AST)B. Riley Weighs in on Asterias Biotherapeutics Inc's FY2017 Earnings (AST)
www.americanbankingnews.com - February 26 at 1:10 AM
Asterias Biotherapeutics (AST) Earns Buy Rating from Analysts at B. RileyAsterias Biotherapeutics (AST) Earns Buy Rating from Analysts at B. Riley
www.americanbankingnews.com - February 25 at 2:06 PM
Benzingas Top Upgrades, Downgrades For February 22, 2018 - BenzingaBenzinga's Top Upgrades, Downgrades For February 22, 2018 - Benzinga
www.benzinga.com - February 22 at 3:38 PM
Asterias Biotherapeutics Inc (AST) Receives Consensus Rating of "Hold" from BrokeragesAsterias Biotherapeutics Inc (AST) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 22 at 9:51 AM
Notable Friday Option Activity: AST, WIFI, PTCT - NasdaqNotable Friday Option Activity: AST, WIFI, PTCT - Nasdaq
www.nasdaq.com - February 17 at 3:37 PM
Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer ... - GlobeNewswire (press release)Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer ... - GlobeNewswire (press release)
globenewswire.com - February 17 at 3:37 PM
Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer Immunotherapy ProgramAsterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer Immunotherapy Program
finance.yahoo.com - February 15 at 3:38 PM
Short Interest in Asterias Biotherapeutics Inc (AST) Expands By 0.1%Short Interest in Asterias Biotherapeutics Inc (AST) Expands By 0.1%
www.americanbankingnews.com - January 30 at 2:44 PM
Asterias Biotherapeutics (AST) Stock Rating Lowered by Zacks Investment ResearchAsterias Biotherapeutics (AST) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 19 at 6:02 PM
Short Interest in Asterias Biotherapeutics Inc (AST) Declines By 2.6%Short Interest in Asterias Biotherapeutics Inc (AST) Declines By 2.6%
www.americanbankingnews.com - January 11 at 2:36 AM
Asterias Biotherapeutics (AST) "Buy" Rating Reaffirmed at HC WainwrightAsterias Biotherapeutics' (AST) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - January 8 at 7:26 AM
33 Stocks Moving In Thursdays Mid-Day Session | Benzinga - Benzinga33 Stocks Moving In Thursday's Mid-Day Session | Benzinga - Benzinga
www.benzinga.com - January 4 at 4:43 PM
Asterias Biotherapeutics reports milestone targets for 2018 - Seeking AlphaAsterias Biotherapeutics reports milestone targets for 2018 - Seeking Alpha
seekingalpha.com - January 4 at 4:43 PM
Asterias Biotherapeutics Reports Milestone Targets for 2018 - Nasdaq - NasdaqAsterias Biotherapeutics Reports Milestone Targets for 2018 - Nasdaq - Nasdaq
www.nasdaq.com - January 4 at 3:43 PM
Asterias Biotherapeutics Reports Milestone Targets for 2018Asterias Biotherapeutics Reports Milestone Targets for 2018
finance.yahoo.com - January 4 at 10:07 AM
ETFs with exposure to Asterias Biotherapeutics, Inc. : December 28, 2017ETFs with exposure to Asterias Biotherapeutics, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 4:25 PM
Asterias Biotherapeutics Inc (AST) Short Interest Up 6.3% in DecemberAsterias Biotherapeutics Inc (AST) Short Interest Up 6.3% in December
www.americanbankingnews.com - December 27 at 6:38 PM
Asterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Asterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 12:57 PM
Wired News – Asterias Reports Enrollment and Dosing of Last Subject in SciStar Trial In Treatment of Severe Spinal Cord InjuryWired News – Asterias Reports Enrollment and Dosing of Last Subject in SciStar Trial In Treatment of Severe Spinal Cord Injury
finance.yahoo.com - December 21 at 10:12 AM
BioTime to Participate in The LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018 - Business Wire (press release)BioTime to Participate in The LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018 - Business Wire (press release)
www.businesswire.com - December 20 at 3:42 PM
BRIEF-Asterias Biotherapeutics Completes Enrollment Of Entire SCiStar StudyBRIEF-Asterias Biotherapeutics Completes Enrollment Of Entire SCiStar Study
www.reuters.com - December 19 at 4:40 PM
Asterias Biotherapeutics Completes Enrollment of Entire SCiStar Study - NasdaqAsterias Biotherapeutics Completes Enrollment of Entire SCiStar Study - Nasdaq
www.nasdaq.com - December 19 at 10:15 AM
Asterias Biotherapeutics Completes Enrollment of Entire SCiStar StudyAsterias Biotherapeutics Completes Enrollment of Entire SCiStar Study
finance.yahoo.com - December 19 at 10:15 AM

SEC Filings

Asterias Biotherapeutics (NYSEAMERICAN:AST) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Asterias Biotherapeutics (NYSEAMERICAN AST) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.